Agios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency

NEXT STORY
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
PREV STORY
Onconova Therapeutics Announces Data on Genomic Profiles of Higher Risk Myelodysplastic Syndromes Patients Refractory to Azacitidine Therapy Enrolled into the Pivotal INSPIRE Trial and Updated Oral Rigosertib Data Informing a Potential Adaptive Clinical Trial Design at the American Society of Hematology 2019 Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Chiesi Group receives European Marketing Authorization for Trimbow® inhalation powder (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) delivered through NEXThaler, an extrafine formulation fixed triple combination therapy for the treatment of moderate to severe COPD

author_avatar
NASDAQ Market News

SELLAS Appoints Steering Committee of Leading Acute Myeloid Leukemia Experts for Its Ongoing Phase 3 REGAL Clinical Trial in AML

author_avatar
NASDAQ Market News

CorMedix Inc. to Present at the Jefferies Virtual Healthcare Conference

author_avatar
NASDAQ Market News